Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NYSE:ANVS NASDAQ:BFRG NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.52+1.3%$1.67$1.10▼$4.10$55.35M-0.9512,182 shs4,448 shsANVSAnnovis Bio$2.66-5.4%$2.47$1.11▼$11.69$54.76M1.57383,936 shs475,137 shsBFRGBullfrog AI$1.51+0.7%$1.67$1.23▼$4.84$14.12M0.48380,810 shs161,672 shsPDSBPDS Biotechnology$1.15-4.2%$1.45$0.85▼$4.32$54.85M1.21476,197 shs289,150 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-0.99%-3.23%0.00%-12.28%-57.26%ANVSAnnovis Bio+1.18%-2.08%+6.62%+127.42%-77.37%BFRGBullfrog AI+0.67%-1.32%-12.28%-9.64%-44.03%PDSBPDS Biotechnology-0.83%-7.69%-25.93%+11.11%-70.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye2.1291 of 5 stars3.05.00.00.02.90.00.0ANVSAnnovis Bio1.5825 of 5 stars3.51.00.00.00.61.70.6BFRGBullfrog AI0.7502 of 5 stars0.02.00.00.03.32.50.0PDSBPDS Biotechnology1.1786 of 5 stars3.71.00.00.01.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.00Hold$9.00492.11% UpsideANVSAnnovis Bio 3.00Buy$18.00577.20% UpsideBFRGBullfrog AI 0.00N/AN/AN/APDSBPDS Biotechnology 3.33Buy$9.00682.61% UpsideCurrent Analyst Ratings BreakdownLatest BFRG, PDSB, ANVS, and ANL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.006/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M11.22N/AN/A$0.69 per share2.20ANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/ABFRGBullfrog AI$60K237.07N/AN/A$0.57 per share2.65PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)BFRGBullfrog AI-$6.99M-$0.81N/A∞N/AN/A-163.23%-139.94%8/6/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)Latest BFRG, PDSB, ANVS, and ANL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ANVSAnnovis Bio-$0.36N/AN/AN/AN/AN/A8/12/2025Q2 2025PDSBPDS Biotechnology-$0.24N/AN/AN/AN/AN/A5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai Nortye0.021.411.41ANVSAnnovis BioN/A10.6810.68BFRGBullfrog AIN/A4.874.87PDSBPDS Biotechnology0.292.332.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%ANVSAnnovis Bio15.83%BFRGBullfrog AI0.96%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AANVSAnnovis Bio20.80%BFRGBullfrog AI33.90%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableANVSAnnovis Bio319.49 million15.43 millionOptionableBFRGBullfrog AI49.42 million6.22 millionNot OptionablePDSBPDS Biotechnology2045.71 million41.51 millionOptionableBFRG, PDSB, ANVS, and ANL HeadlinesRecent News About These CompaniesPDS wasn’t a bad deal, few greedy individuals cannibalised it with self-serving interests – John JinaporJuly 16 at 11:29 PM | modernghana.comMPDS deal was not bad but greedy people decided to cannibalise the process - JinaporJuly 16 at 11:29 PM | ghanaweb.comGEnergy Minister blames ‘greedy individuals’ for undermining ‘otherwise good’ PDS dealJuly 16 at 6:28 PM | myjoyonline.comMPDS to pay final dividend of ₹1.70, ex-date due tomorrow; last day today to trade sharesJuly 16 at 5:14 AM | moneycontrol.comThe top headlines for PDS Health’s busy 2025 so farJuly 12, 2025 | beckersdental.comBPDS Biotechnology stock rises after trial meets criteria for expansionJuly 10, 2025 | investing.comPDS Biotechnology Shares Climb Following Trial Expansion MilestoneJuly 10, 2025 | msn.comPDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 ResultsJuly 10, 2025 | globenewswire.comASIC consults on simplifying PDS guidanceJuly 10, 2025 | professionalplanner.com.auPAP: over 11k kg of PDS rice seized in a private premiseJuly 10, 2025 | uniindia.comUOne arrested for smuggling PDS rice near TiruchiJuly 7, 2025 | thehindu.comPDS Health adds practices in 5 statesJuly 3, 2025 | beckersdental.comB3 booked for illegally transporting PDS food grains stock for sale in ThaneJuly 3, 2025 | theprint.inTPDS arm inks pact to acquire 60% stake in GSC LinkJuly 3, 2025 | business-standard.comBPDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC WainwrightJuly 1, 2025 | marketbeat.comTwo errant traders arrested; 79.3 quintals of PDS rice seizedJune 25, 2025 | thehindu.comPDS Health Raises Over $1.9 Million Through Smile Generation to Support charity: water's Clean Water ProjectsJune 25, 2025 | kxan.comKPDS Biotechnology Corporation (PDSB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPDS Health ranked among most community-minded companiesJune 13, 2025 | beckersdental.comBUnpacking the PDS PhenomenonJune 11, 2025 | devdiscourse.comDPDS rice will be distributed till June 30: Civil Supplies deptJune 11, 2025 | thehansindia.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFRG, PDSB, ANVS, and ANL Company DescriptionsAdlai Nortye NASDAQ:ANL$1.52 +0.02 (+1.33%) Closing price 03:24 PM EasternExtended Trading$1.52 0.00 (0.00%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Annovis Bio NYSE:ANVS$2.66 -0.15 (-5.41%) Closing price 03:59 PM EasternExtended Trading$2.70 +0.04 (+1.58%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Bullfrog AI NASDAQ:BFRG$1.51 +0.01 (+0.67%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.00 (+0.33%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.PDS Biotechnology NASDAQ:PDSB$1.15 -0.05 (-4.17%) Closing price 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
